Myriad Genetics Inc

Day range

—

Open

—

Prev close

$5.74

Volume

0

Market cap

$550.59M

Shares out

95.65M

P/E

—

P/S

0.69

P/B

2.05

P/FCF

—

ROE

-48.0%

ROA

-21.2%

Debt/Equity

0.45

Div yield

0.00%

As of Nov 9, 2026

• Executive compensation changeNov 9, 2026

  Retention Option Awards received by the Company's named executive officers, and the number of shares subject to such awards, are set forth in the table below: Benjamin R. Wheeler, Chief Financial Officer — 121,379 shares; Mark S. Verratti, Chief Operating Officer — 146,933 shares; Dale Muzzey, Chief Scientific Officer — 92,632 shares.

• Cybersecurity incidentNov 5, 2026

  On November 2, 2026, Myriad Genetics, Inc. (the "Company") detected unauthorized access within its information technology network environment. Upon discovery, the Company promptly initiated its incident response procedures to contain the activity, assess and investigate the nature and scope of the incident, and implement appropriate remedial measures, including temporarily suspending its testing operations and order management systems and resetting certain system credentials.

• Quarterly earningsNov 4, 2026

  On November 4, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

• Divestiture agreementOct 20, 2026

  On October 19, 2026, Myriad Genetics, Inc. and Laboratory Corporation of America entered into an Asset Purchase Agreement. Pursuant to the Purchase Agreement, the Company has agreed to sell and assign to Buyer, and Buyer has agreed to purchase and assume from the Company, certain assets and liabilities of the Company's prenatal health business ... in exchange for $210 million in cash, plus the value of the inventory of the Business at closing.

• Executive compensation changeOct 9, 2026

  Pursuant to the terms of the Separation Agreement... Mr. Donnelly will receive a lump sum severance payment of $1,322,294. In addition, (i) the vesting of all outstanding time-based equity awards... will be accelerated...

Days to cover

5.3

Short interest

9.27M

Avg volume

1.74M

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates
  positiveZacks Investment Research· Nov 4, 2026
• Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments
  neutralGlobeNewswire Inc.· Sep 24, 2026
• Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
  positiveGlobeNewswire Inc.· Sep 16, 2026
• MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Aug 7, 2026
• MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
  negativeGlobeNewswire Inc.· Aug 5, 2026